Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome, Sapienza University of Rome, shares an overview of ongoing clinical trials for the disease modifying treatment of Parkinson’s disease (PD). One key approach is the targeting of α-synuclein and in this space, prasinezumab is one of the most advanced investigational agents. The antibody targets aggregated α-synuclein to prevent cell-to-cell transmission. While the Phase II PASADENA trial missed the primary efficacy outcome of change on the MDS-UPDRS global score, several positive signals were seen in secondary endpoints, including a trend towards benefit on the UPDRS Part III, which measures decline in motor function. The Phase IIb PADOVA trial in patients with more advanced symptoms is ongoing, utilizing change in UPDRS Part III as the primary outcome measure. Other α-synuclein-targeting agents are also in development, including small molecule α-syn misfolding inhibitors, such as UCB0599 which is currently undergoing Phase II evaluation, and vaccinations, including ACI-7104.056. Other strategies include LRRK2 inhibition (BIIB122) and allosteric activation of beta-glucocerebrosidase (BIA 28-6156). This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
